Siqing Fu

Associate Professor

  • 4256 Citations
  • 35 h-Index
19932018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Neoplasms Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Mutation Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Survival Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2018

oxaliplatin
Clinical Trials, Phase I
Liver Neoplasms
Liver
Toxicity
1 Citations

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Patnaik, A., Gordon, M., Tsai, F., Papadopoulous, K., Rasco, D., Beeram, S. M., Fu, S., Janku, F., Hynes, S. M., Gundala, S. R., Willard, M. D., Zhang, W., Lin, A. B. & Hong, D., Sep 1 2018, In : Cancer chemotherapy and pharmacology. 82, 3, p. 407-418 12 p.

Research output: Contribution to journalArticle

Bispecific Antibodies
Epithelial-Mesenchymal Transition
Epidermal Growth Factor Receptor
Appointments and Schedules
Pharmacokinetics

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (Cancer Chemotherapy and Pharmacology, (2018), 82, 3, (407-418), 10.1007/s00280-018-3623-7)

Patnaik, A., Gordon, M., Tsai, F., Papadopoulos, K. P., Rasco, D., Beeram, M., Fu, S., Janku, F., Hynes, S. M., Gundala, S. R., Willard, M. D., Zhang, W., Lin, A. B. & Hong, D. S., Sep 1 2018, In : Cancer chemotherapy and pharmacology. 82, 3, 1 p.

Research output: Contribution to journalComment/debate

Bispecific Antibodies
Chemotherapy
Names
Pharmacology
Drug Therapy
Aurora Kinases
Valproic Acid
Neoplasms
corrigendum
Clinical Trials, Phase I
Confidence Intervals
Neoplasms
Survival
Clinical Trials